CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. The Company's two key clinical development candidates are Seladelpar and Arhalofenate. Seladelpar is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis and the epidemic in nonalcoholic SteatoHepatitis. Arhalofenate is a potential urate-lowering anti-flare therapy for gout that is Phase 3 ready. The Company's pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.

TypePublic
HQNewark, US
Founded1991
Size (employees)21 (est)
Websitecymabay.com
CymaBay Therapeutics was founded in 1991 and is headquartered in Newark, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

CymaBay Therapeutics Office Locations

CymaBay Therapeutics has an office in Newark
Newark, (HQ)
7999 Gateway Blvd
Show all (1)
Report incorrect company information

CymaBay Therapeutics Financials and Metrics

CymaBay Therapeutics Revenue

USD

Net income (Q2, 2018)

(34.5m)

EBIT (Q2, 2018)

(30.8m)

Market capitalization (4-Dec-2018)

520.1m

Closing stock price (4-Dec-2018)

8.8

Cash (30-Jun-2018)

44.7m
CymaBay Therapeutics's current market capitalization is $520.1 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

General and administrative expense

4.9m8.9m9.6m12.4m

R&D expense

4.5m17.0m15.9m18.9m

Operating expense total

9.4m25.9m25.6m31.3m

EBIT

(9.4m)(25.9m)(25.6m)(21.3m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

General and administrative expense

683.0k2.5m1.7m1.7m2.3m2.2m2.5m2.2m2.1m3.7m3.6m3.4m6.9m

R&D expense

703.0k2.6m4.1m3.8m4.3m4.5m4.4m4.1m3.5m4.0m4.0m9.5m23.9m

Operating expense total

1.4m5.1m5.7m5.5m6.5m6.7m6.9m6.3m5.7m7.7m7.6m12.9m30.8m

EBIT

(1.4m)(5.1m)(5.7m)(5.5m)(6.5m)(6.7m)(6.9m)(6.3m)(5.7m)(2.9m)(7.6m)(12.8m)(30.8m)
Annual
USDFY, 2013FY, 2016FY, 2017

Net Income

(10.1m)(26.7m)(27.6m)

Depreciation and Amortization

55.0k29.0k35.0k

Accounts Payable

40.0k(109.0k)412.0k

Cash From Operating Activities

(8.5m)(23.4m)(19.6m)
Quarterly
USDQ1, 2018Q2, 2018

Net Income

(17.0m)(34.5m)

Depreciation and Amortization

12.0k25.0k

Accounts Payable

727.0k25.0k

Cash From Operating Activities

(6.4m)(19.3m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

CymaBay Therapeutics Blogs

CymaBay Therapeutics to Participate in Upcoming Investor Conferences

NEWARK, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three upcoming inv…

CymaBay Therapeutics Presents Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC at The Liver Meeting® 2018

Sustained anti-cholestatic and anti-inflammatory effects observed with no worsening of pruritus through 52 weeks    Results highlight the potential for seladelpar to offer patients an efficacious and safe second line treatment option Efficacy and tolerability were retained in a subset of patients…

CymaBay Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced fina…

CymaBay to Report Third Quarter 2018 Financial Results on Tuesday, November 6

NEWARK, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio web…

CymaBay Announces the Initiation of the Seladelpar Global Phase 3 Registration Study (ENHANCE) for the Treatment of Primary Biliary Cholangitis and Additional Corporate Updates

Phase 3 patient enrollment commenced with multiple investigational sites in the U.S. initiated Team expanded with key hires focused on delivering a high-quality registration package NEWARK, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced tha…

CymaBay Therapeutics Announces Additional Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC will be Presented During the Late-Breaking Session at The Liver Meeting®

52-week analysis highlights the potential for seladelpar to offer patients improved efficacy and better tolerability than existing second line treatment Third consecutive year data from the development of seladelpar in PBC will be highlighted in a late-breaking presentation at The Liver Meeting® …
Show more

CymaBay Therapeutics Company Life and Culture

Report incorrect company information

CymaBay Therapeutics Frequently Asked Questions

  • When was CymaBay Therapeutics founded?

    CymaBay Therapeutics was founded in 1991.

  • How many employees does CymaBay Therapeutics have?

    CymaBay Therapeutics has 21 employees.

  • Who are CymaBay Therapeutics competitors?

    Competitors of CymaBay Therapeutics include Kiniksa Pharmaceuticals, Sartorius Stedim BioOutsource and Neurosearch.

  • Where is CymaBay Therapeutics headquarters?

    CymaBay Therapeutics headquarters is located at 7999 Gateway Blvd, Newark.

  • Where are CymaBay Therapeutics offices?

    CymaBay Therapeutics has an office in Newark.

  • How many offices does CymaBay Therapeutics have?

    CymaBay Therapeutics has 1 office.